Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06347510
Status:
COMPLETED
Last Update Posted:
2024-04-04
First Post:
2024-03-26
Brief Title:
The Level of sST2 in Pediatric Heart Failure
Sponsor:
Eskisehir Osmangazi University
Organization:
Eskisehir Osmangazi University
Study Overview
Official Title:
Does the Level of ST2 in Pediatric Heart Failure Patients Indicate the Likelihood of Cardiovascular Events and Mortality
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Introduction Suppression of tumorigenicity 2 ST2 is a receptor member belongs to the Interleukin-1 IL-1 family The ligand and soluble versions are its two isoforms The interleukin-33-ST2 ligand complexs development provides protection against heart fibrosis and hypertrophy Investigations on heart failure in adults has demonstrated that it does not change by age body mass index BMI creatinine hemoglobin and albumin levels in contrast to NT pro brain natriuretric peptit In adult heart failure patients it has been demonstrated to be an independent predictor of mortality and cardiovascular events The most recent guideline recommends using it as class 2b in the diagnosis of adult heart failure Studies on ST2 in children are rare The purpose of this study is to assess the prognostic value of ST2 for cardiovascular events in young individuals suffering from heart failure
Method The study included pediatric patients 0-18 years old with congenital heart disease or cardiomyopathy who needed medical care as well as surgical or interventional treatment Height weight gender saturation heart failure classification Ross or New York heart Assosiation medications taken the electrocardiogram echocardiography Pro BNP and sST2 values of the patients as well as any hospitalization lower respiratory tract infection organ dysfunction or need for angiography or surgery during follow-up Data on arrhythmia and death were gathered during a 1-year follow-up The SPSS software application was used to carry out the statistical analysis
Method The study included pediatric patients 0-18 years old with congenital heart disease or cardiomyopathy who needed medical care as well as surgical or interventional treatment Height weight gender saturation heart failure classification Ross or New York heart Assosiation medications taken the electrocardiogram echocardiography Pro BNP and sST2 values of the patients as well as any hospitalization lower respiratory tract infection organ dysfunction or need for angiography or surgery during follow-up Data on arrhythmia and death were gathered during a 1-year follow-up The SPSS software application was used to carry out the statistical analysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None